Prognostic and predictive value of changes in tumour cell proliferation in locally advanced breast cancer primarily treated with doxorubicin

Oncology Reports

Volumn 13, Issue 3, 2005, Pages 525-530

  Aas, Turid ^a   Geisler, Stephanie ^a   Helle, Hildegunn ^a   Børresen Dale, Anne Lise ^b   Lønning, Per Eystein ^a   Akslen, Lars Andreas ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Breast cancer; Chemotherapy; TP53; Tumour cell proliferation

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; KI 67 ANTIGEN; TUMOR MARKER;

ARTICLE; BIOSYNTHESIS; BREAST TUMOR; CELL PROLIFERATION; COMPARATIVE STUDY; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MITOSIS; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL PROLIFERATION; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MITOSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 15044361126     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.13.3.525     Document Type: Article

References (30)

1. Amadori D, Volpi A and Maltoni R: Cell proliferation as a predictor of response to chemotherapy in metastatic cancer: a prospective study. Breast Cancer Res Treat 43: 7-14, 1997. (Pubitemid 27090862)
2. Collecchi P, Baldini E, Giannessi P, et al: Primary Chemotherapy in locally advanced breast cancer (LABC): Effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers. Eur J Cancer 34: 1701-1704, 1998. (Pubitemid 28474222)
3. Daidone M, Veneroni S, Benini E, et al: Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. Int J Cancer 84: 580-586, 1999.
4. Sjøstrøm J: Predictive factors for response to chemotherapy in advanced breast cancer. Acta Oncol 41: 334-345, 2002.
5. Ravaioli A, Bagli L, Zucchini A, et al: Prognosis and prediction of response in breast cancer: the current role of the main biological markers. Cell Prof 31: 113-126, 1998. (Pubitemid 28529020)
6. Chang J, Powles TJ, Allred DC, et al: Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17: 3058-3063, 1999. (Pubitemid 29470633)
7. Aas T, Børresen A-L, Geisler S, et al: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med 2: 811-814, 1996. (Pubitemid 26225099)
8. Geisler S, Lønning PE, Aas T, et al: Influence of TP53 gene alterations and c-erB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 61: 2505-2512, 2001. (Pubitemid 32685830)
9. Lonning PE: Study of suboptimum treatment response: lessons from breast cancer. Lancet Oncol 4: 177-185, 2003.
10. Aas T, Geisler S, Eide GE, et al: Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 39: 438-446, 2003. (Pubitemid 36173687)
11. Billgren AM, Rutqvist LE, Tani E, Wilking N, Fornander T and Skoog L: Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival. Acta Oncol 38: 597-601, 1999. (Pubitemid 29333740)
12. Nizzoli R, Bozetti C, Naldi N, et al: Comparison of the results of immunocytochemical assays for biologic variables on preoperative fine-needle aspirates and on surgical specimens of primary breast carcinomas. Cancer 90: 61-66, 2000. (Pubitemid 30120290)
13. Aas T, Geisler S, Paulsen T, et al: Primary systemic therapy with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncol 35 (suppl 5): 5-8, 1996.
14. Hayward JL, Rubens RD, Carbone PP, Heuson JC, Kumaoka S and Segaloff A: Assessment of response to therapy in advanced breast cancer. Br J Cancer 35: 292-298, 1977.
15. Elston CW and Ellis IO: Patological prognostic factors in breast cancer. The value of histological grade in breast cancer experience from a long-term follow-up. Histopathology 19: 403-410, 1991.
16. Thorsen T: Occupied and unoccupied nuclear oestradiol receptor in human breast tumors: relation to oestradiol and progesterone cytosol receptors. J Steroid Biochem 10: 661-668, 1979.
17. Salvesen H, Iversen OE and Akslen LA: Prognostic significance of angiogenesis and Ki-67, p53 and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 17: 1382-1390, 1999. (Pubitemid 29220843)
18. Andersen TI and Børresen A-L: Alterations of the TP-53 gene as a potential prognostic markers in breast carcinomas. Diagn Mol Pathol 4: 203-211, 1995.
19. Børresen A-L: Constant denaturant gel electrophoresis (CDGE) in mutation screening. In: Technologies for Detection of DNA Damage and Mutation. G.P. Pfeifer (ed). Plenum Press, New York, pp267-279, 1996.
20. Gardin G, Alama A, Rosso R, et al: Relationship of tumor cell kinetics induced by primary chemotherapy to tumor regression and prognosis in locally advanced breast cancer. Breast Cancer Res Treat 32: 311-318, 1994. (Pubitemid 24351378)
21. Bottini A, Berruti A, Bersiga A, et al: Effect of neoadjuvant chemotherapy on Ki-67 labeling index, e-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer Res 16: 3105-3110, 1996. (Pubitemid 26390257)
22. Niskanen E, Blomquist C, Franssila K, Hietanen P and Wasenius VM: Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br J Cancer 76: 917-922, 1997. (Pubitemid 27401944)
23. Ellis PA, Smith LE, Detre S, et al: Reduced apoptosis and proliferation and increased Bcl-2 in recidual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 48: 107-116, 1998. (Pubitemid 28156355)
24. Bottini A, Berruti A, Bersiga A, et al: Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. Br J Cancer 85: 1106-1112, 2001.
25. Frassoldati A, Adami F, Banzi C, Criscuolo M, Piccini L and Silingardi V: Changes of biological features in breast cancer cells determined by primary chemotherapy. Breast Cancer Res Treat 44: 185-192, 1997. (Pubitemid 27296377)
26. Linn SC, Pinedo HM, van Ark-Otte J, et al: Expression of drug resistance proteins in breast cacner, in relation to chemotherapy. Int J Cancer 71: 787-795, 1997. (Pubitemid 27237200)
27. Paradiso A, Mangia A, Tortora G, et al: Biological and clinical relevance of proliferative activity in inflammatory breast cancer. Int J Cancer 6: 563-567, 1995.
28. Honkoop AH, van Diest PJ, de Jong JS, et al: Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 77: 621-626, 1998. (Pubitemid 28059470)
29. Pierga JY, Leroyer A, Viehl P, Mosseri V, Chevillard S and Magdalena H: Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer. Breast Cancer Res Treat 37: 57-64, 1996. (Pubitemid 26028246)
30. Railo M, Lundin J, Haglund C, von Smitten K, von Bogulawsky K and Nordling S: Ki-67, p53, ER-receptors, ploidy and s-phase as prognostic factors in T1 node negative breast cancer. Acta Oncol 36: 369-374, 1997. (Pubitemid 27298555)